Pancreatic Cancer Non-resectable
Conditions
Brief summary
The study consists of a 25 ml blood sample collection: * Before the start of treatment * Approximately 2 months after the start of induction chemotherapy * At the end of induction chemotherapy * Prior to local treatment (radiotherapy, surgery) * At the time of tumor progression Collection of tumor material: * During the initial diagnostic biopsy * On the operating room in case of surgery * At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.
Interventions
OTHERcollection of blood and tumor samples
The study consists of the collection of a 25 ml blood sample: * Before the start of treatment * Approximately 2 months after the start of induction chemotherapy * At the end of induction chemotherapy * Prior to local treatment (radiotherapy, surgery) * At the time of tumor progression At the time of collection of tumor material: * During the initial diagnostic biopsy * On the operating room in case of surgery * During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities.
Sponsors
Institut Paoli-Calmettes
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Non-metastatic pancreatic adenocarcinoma that is not immediately resectable (borderline and locally advanced tumors according to the NCCN 2020 classification) * No previous treatment with surgery or chemotherapy * Age \> 18 years * General condition WHO 0-2 (patient whose general condition can allow medical treatment or surgery) * Therapeutic management at the Paoli-Calmettes Institute * Signature of the informed consent specific to the PANDORE-PANC study * Patient affiliated to a social security system or benefiting from such a system
Exclusion criteria
* Metastatic disease * Pancreatic tumor of a histological type other than adenocarcinoma * Other tumor under treatment or for which treatments have been completed for \< 1 year * Pregnant or breastfeeding women * Person in an emergency situation * Person of legal age under legal protection (guardianship, curatorship or safeguard of justice) or unable to give consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Predict response to systemic therapies in patients with non-metastatic pancreatic adenocarcinoma | up to 6 years | Analysis of the impact of identified biomarkers on overall patient survival and tumour response |
Contacts
Primary ContactDominique GENRE, MD
Outcome results
None listed